Free Diabetes and Endocrinology CME

The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients.

By the end of Oncology Patients at High Risk of Bone Fracture, you will be able to:
• Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
• Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
Identify present pharmacotherapeutic treatments for management of a patient receiving • AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
• Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case

Target Audience:
Oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.

The Evolution of Insulin Replacement Therapy consists of 4 presentations with discussion:
• Session 1: Insulin Options for Diabetes: Update on their Evolution
• Session 2: Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options
• Session 3: Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider
• Session 4: The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options

At the conclusion of The Evolution of Insulin Replacement Therapy, you will be able to:
• Identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations
• Discuss the clinical importance of similarities and differences between a biosimilar insulin and a reference insulin
• Recognize the indications for advancement to insulin replacement therapy for people with T2DM
• Identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations
• Describe initiation and titration methods for new insulin-based therapies to optimize achievement of glycemic goals while minimizing adverse effects
• Discuss strategies to overcome patient and clinician barriers to the successful initiation and utilization of insulin therapy in the context of the new insulin-based therapies, and monitoring and delivery devices

Target Audience:
This program is intended for US-based primary care providers, clinical endocrinologists/diabetologists, nephrologists, cardiologists, emergency department specialists, pharmacists, and other clinicians caring for patients with type 2 diabetes mellitus (T2DM).

Hunter syndrome is an X-linked recessive genetic disease characterized by a deficiency of lysosomal enzymes responsible for the hydrolysis of glycosaminoglycans (GAGs), with males more likely to develop disease and females more likely to be carriers.

After reviewing Treatment strategies in Hunter Syndrome, you will be able to:
• Describe the importance of earlier treatment and diagnosis of Hunter syndrome in patients
• Determine the likelihood of Hunter syndrome using with established diagnosis methods, given a patient case
• Describe options available to treat Hunter syndrome and design a medical plan to treat a patient with Hunter syndrome
• Describe present barriers to care in the treatment of patients with Hunter syndrome

After completing Adult Growth Hormone Deficiency (GHD), you will be able to:
• Summarize present guidelines for the diagnosis of GHD
• Describe the underlying pathophysiological and typical clinical features of GHD as they pertain to therapeutic targets.
• Given a patient with GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation.
• Assess and properly manage the significant comorbidities that are associated with GHD and therefore increase mortality in patients with GHD
• Evaluate patient cases during follow-up visits in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence.
In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audiences:
Healthcare professionals specializing in endocrinology and those who otherwise commonly care for or clinically encounter adult patients with GHD.